Trokendi XR (Topiramate) Patent Expiration, LOE Window & CMS Spending

Trokendi XR (Topiramate) by Supernus: FDA Orange Book LOE 2028-04-04, 15 AB generics, $44.3M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSupernus
FDA Application & PathwayN201635 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-04-04
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors15
2024 CMS Total Public Spend$44.3M
2024 Medicare Part D Spend$17.9M
2024 Medicaid Spend$26.3M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 19.1% 2-yr change)